OFF-LABEL PROMOTION IS UNLIKELY TO PROVIDE INFORMATION BENEFIT TO PHYSICIANS, FDA's TEMPLE SAYS; SINGLE PIVOTAL STUDIES ARE "NOT CHEAPER" AND "HIGH RISK"